Please assess the completion status of the following clinical trial:

Trial Title: Initiation of Continuous Glucose Monitoring at Diagnosis of Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~To be eligible for the study, a child must meet the following criteria:~1. Diagnosis of type 1 diabetes according to American Diabetes Association diagnostic criteria~2. Time since diagnosis of no longer than one month~3. Age between 2 and 17 years~4. Parental consent (and assent from the child where applicable) to participate in the study~5. No severe medical conditions, which in the opinion of the investigators are likely to hinder participation in this clinical trial.~To be eligible for the study, a parent must meet the following criteria:~1. Parent or legal guardian of a child with type 1 diabetes meeting the child criteria outlined above~2. Age of 18.0 years or older~3. Parent comprehends written English~4. Parent understands the study protocol and signs the informed consent document~Exclusion Criteria:~The presence of any of the following is an exclusion for the study:~1. Child has a medical disorder that in the judgment of the investigator will interfere with completion of any aspect of the protocol (e.g., pregnancy, kidney disease, adrenal insufficiency, skin condition that may hinder sensor application).~2. Child has a neurologic disorder that in the judgment of the investigator will affect completion of the protocol~3. Current use of oral glucocorticoids or other medications, which in the judgment of the investigator would be a contraindication to participation in the study~4. Child is unable to completely avoid acetaminophen for duration of study

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- CGM at diagnosis of T1D (Type: EXPERIMENTAL): Participants start non-adjunctive use of CGM at diagnosis of T1D and continue for 6 months.
- Usual Care (Type: NO_INTERVENTION): Participants receive usual care for T1D for 6 months post diagnosis.

Based on this trial design, predict the completion outcome and termination type (if applicable).